Additional file 5 of Integrated single-cell transcriptomics of cerebrospinal fluid cells in treatment-naïve multiple sclerosis

Additional file 5: Table S1. Subject demographics and technical information on scRNA-Seq. (Table 1.1) Composition of the three datasets, subject demographics of included multiple sclerosis (MS, n = 20) and control (IIH/HC = Ctrl, n = 11) patients, MRI features and CSF findings are listed. For dataset 3, non-included samples from Ramesh et al. [13] are listed (grayed out) and their exclusion criteria are shown. See methods for the primary source of the three datasets. Column legend: IIH = idiopathic intracranial hypertension, MS = multiple sclerosis, CIS = clinically isolated syndrome, f = female, m = male, rel_gd = relapse, lesions with gadolinium enhancement detected on magnetic resonance imaging (MRI), rel_nogd = relapse, no lesion with gadolinium enhancement on MRI, MS-typical MRI = MS-typical lesion pattern in characteristic locations (ovoid periventricular lesions/Dawson fingers, cortical or juxtacortical, infratentorial and spinal cord) (1) / no Ms-typical lesion pattern (0), active = active relapse, Gd +  = gadolinium detected (1) or not detected (0) in MRI lesion, months from onset = months from first symptoms until sample collection, cell = cell count/µL obtained via lumbar puncture, lympho = lymphocytes/µL of cerebrospinal fluid (CSF), granulo = granulocytes/µL of CSF, rbc = red blood cell count/µL CSF, protein = obtained protein concentration in mg/L CSF, lactate = CSF lactate in nmol/L, glucose = CSF glucose in mg/dL, OCB +  = any oligoclonal bands (OCB) detected in CSF (1) or not detectable (0). Barrier disruption = no barrier disruption (0) or present barrier disruption (1). CSF index = derived from the Reiber scheme [54] (IgG CSF/IgG serum index compared to the albumin CSF/albumin serum index), no barrier disruption (none), intrathecal immunoglobulin synthesis (Ig only), intrathecal immunoglobulin synthesis plus barrier disruption (barrier_and_Ig). IgG-index > 0.7 = IgG synthesis in the CSF. All parameters were obtained within 24 h of CSF sampling. (Table 1.2) Technical information on scRNA-seq results of all patients (MS, n = 20) and healthy controls (Ctrl, n = 11) included in the study are listed. The sequencing technique for generation of the 10 × libraries is listed for the different datasets (10 × Genomics scRNA-seq kit version). Furthermore, the total number of measured cells after sequencing and genome alignment (total cells per sample) and the average number of detected genes per cells (average gene per cell) used for downstream analysis is depicted.